article

Vaccine for a Deadly Spike Protein

United States

HJF scientist Dr. Gordon Joyce spent much of 2020 focused on understanding and documenting the structural biology of the novel coronavirus, SARS-CoV-2. As the head of the Structural Biology Lab at the Walter Reed Army Institute of Research, he successfully produced the most detailed atomic level view of the structure of the SARS-CoV-2 spike protein receptor binding domain, which is the part of the virus that binds to the lungs. This detailed understanding of the structure has been critical to vaccine discovery and development efforts.  

 

Gordan Joyce

 

In related work, Dr. Morgane Rolland, an HJF viral geneticist with the U.S. Military HIV Research Program, conducted genetic analysis of sequences from more than 27,000 individuals infected with SARS-CoV-2 and found that the virus has mutated minimally since its initial outbreak. Her work suggests that one vaccine may be sufficient to combat global infections. 

Their research is part of the coronavirus vaccine development at the Emerging Infectious Diseases Branch of the Walter Reed Army Institute of Research. Led by Army researcher Dr. Kayvon Modjarrad, these efforts have developed a vaccine candidate known as SpFN (Spike Ferritin Nanoparticle). The SpFN vaccine is unique among other COVID-19 vaccines in development because the nanoparticle’s multifaceted surface has been engineered to present specific pieces of the coronavirus spike protein (the part of the virus that attaches to the lungs) to the immune system many times over to elicit a strong immune response.  

“The emergence of coronaviruses in human populations is accelerating and we need to be prepared for the eventuality that the current coronavirus mutates or other coronaviruses arise,” said Dr. Modjarrad. “That’s why we need a vaccine, like the one we’re developing, that can be used to protect broadly against all coronaviruses.” 

The researchers are taking a strategic long-term approach to vaccine development. In the future, the vaccine might be adapted so that different faces of the nanoparticle present different coronaviruses to the immune system at the same time. In addition, the vaccine platform could pave the way for a universal vaccine to protect against not only the current virus, but also other known and unknown coronaviruses that could arise. 

Back to the Annual Report